《Nature,6月11日,Hematological features of persons with COVID-19》

  • 来源专题:COVID-19科研动态监测
  • 编译者: zhangmin
  • 发布时间:2020-06-12
  • Hematological features of persons with COVID-19

    Qiubai Li, Yulin Cao, Lei Chen, Di Wu, Jianming Yu, Hongxiang Wang, Wenjuan He, Li Chen, Fang Dong, Weiqun Chen, Wenlan Chen, Lei Li, Qijie Ran, Qiaomei Liu, Wenxiang Ren, Fei Gao, Zhichao Chen, Robert Peter Gale & Yu Hu

    Leukemia (2020)

    Abstract

    We studied admission and dynamic demographic, hematological and biochemical co-variates in 1449 hospitalized subjects with coronavirus infectious disease-2019 (COVID-19) in five hospitals in Wuhan, Hubei province, China. We identified two admission co-variates: age (Odds Ratio [OR] = 1.18, 95% Confidence Interval [CI] [1.02, 1.36]; P = 0.026) and baseline D-dimer (OR = 3.18 [1.48, 6.82]; P = 0.003) correlated with an increased risk of death in persons with COVID-19. We also found dynamic changes in four co-variates, Δ fibrinogen (OR = 6.45 [1.31, 31.69]; P = 0.022), Δ platelets (OR = 0.95 [0.90–0.99]; P = 0.029), Δ C-reactive protein (CRP) (OR = 1.09 [1.01, 1.18]; P = 0.037), and Δ lactate dehydrogenase (LDH) (OR = 1.03 [1.01, 1.06]; P = 0.007) correlated with an increased risk of death. The potential risk factors of old age, high baseline D-dimer, and dynamic co-variates of fibrinogen, platelets, CRP, and LDH could help clinicians to identify and treat subjects with poor prognosis.

  • 原文来源:https://www.nature.com/articles/s41375-020-0910-1
相关报告
  • 《Nature,4月24日,COVID-19 in persons with haematological cancers》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-04-25
    • COVID-19 in persons with haematological cancers Wenjuan He, Lei Chen, Li Chen, Guolin Yuan, Yun Fang, Wenlan Chen, Di Wu, Bo Liang, Xiaoting Lu, Yanling Ma, Lei Li, Hongxiang Wang, Zhichao Chen, Qiubai Li & Robert Peter Gale Leukemia (2020) Abstract Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised.
  • 《Nature,5月18日,COVID-19 in persons with chronic myeloid leukaemia》

    • 来源专题:COVID-19科研动态监测
    • 编译者:zhangmin
    • 发布时间:2020-05-19
    • COVID-19 in persons with chronic myeloid leukaemia Weiming Li, Danyu Wang, Jingming Guo, Guolin Yuan, Zhuangzhi Yang, Robert Peter Gale, Yong You, Zhichao Chen, Shiming Chen, Chucheng Wan, Xiaojian Zhu, Wei Chang, Lingshuang Sheng, Hui Cheng, Youshan Zhang, Qing Li, Jun Qin, Hubei Anti-Cancer Association, Li Meng & Qian Jiang Leukemia (2020) Abstract We studied by questionnaire 530 subjects with chronic myeloid leukaemia (CML) in Hubei Province during the recent SARS-CoV-2 epidemic. Five developed confirmed (N = 4) or probable COVID-19 (N = 1). Prevalence of COVID-19 in our subjects, 0.9% (95% Confidence Interval, 0.1, 1.8%) was ninefold higher than 0.1% (0, 0.12%) reported in normals but lower than 10% (6, 17%) reported in hospitalised persons with other haematological cancers or normal health-care providers, 7% (4, 12%). Co-variates associated with an increased risk of developing COVID-19 amongst persons with CML were exposure to someone infected with SARS-CoV-2 (P = 0.037), no complete haematologic response (P = 0.003) and co-morbidity(ies) (P = 0.024). There was also an increased risk of developing COVID-19 in subjects in advanced phase CML (P = 0.004) even when they achieved a complete cytogenetic response or major molecular response at the time of exposure to SARS-CoV-2. 1 of 21 subjects receiving 3rd generation tyrosine kinase-inhibitor (TKI) developed COVID-19 versus 3 of 346 subjects receiving imatinib versus 0 of 162 subjects receiving 2nd generation TKIs (P = 0.096). Other co-variates such as age and TKI-therapy duration were not significantly associated with an increased risk of developing COVID-19. Persons with these risk factors may benefit from increased surveillance of SARS-CoV-2 infection and possible protective isolation.